Clinical Trial

Suzetrigine for Acute Pain Control in Patients With Multiple Rib Fractures

Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Summary
Rib fractures cause a significant amount of pain and are associated with an increased risk of lung infections, long hospitalization, and increased cost. Effective pain control is the cornerstone of management to improve lung function and minimize complications. Most often this is done with a multimodal pain routine consisting of: acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), topical lidocaine, muscle relaxants, and opioids. However, suzetrigine is a promising alternative to treat acute pain associated with rib fractures. We think the addition of suzetrigine to a multimodal pain regimen will improve pain and decrease opioid use.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-25; most recent amendment 2025-12-04.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-11-14
Trial Details
NCT Number NCT07145346
Lead Sponsor University of California, Irvine
Conditions Rib Fractures
Enrollment 80 participants
Start Date 2025-11-13
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2025-12-08